Physician profile
Asad Khan
NPI 1154483949
$3,893.83
in general payments reported to CMS, 2019-2025
23 companies · $641 in 2025
The $641 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284 · 2020: $178 · 2021: $637 · 2022: $439 · 2023: $877 · 2024: $837 · 2025: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,037 · Education: $170 · Travel and Lodging: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,037.20 |
| Education | $170.21 |
| Travel and Lodging | $147.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $487.59 | 2021-2024 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $460.96 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $444.82 | 2022-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $311.89 | 2020-2024 | Jynarque |
| Medtronic, INC. | $297.89 | 2023-2025 | Venaseal |
| Travere Therapeutics, INC. | $296.14 | 2023-2025 | Filspari |
| Vifor Pharma, INC. | $264.30 | 2021-2025 | Veltassa |
| Mallinckrodt Hospital Products INC. | $186.65 | 2020-2021 | |
| Boston Scientific Corporation | $172.88 | 2025 | Wavewriter Alpha Prime 16 |
| Ardelyx, INC. | $147.36 | 2024 | Xphozah 30 Mg, Ibsrela |
| Veloxis Pharmaceuticals, INC. | $124.96 | 2022 | |
| Baxter Healthcare | $116.88 | 2019 | |
| Novo Nordisk INC | $93.27 | 2024 | |
| Novartis Pharmaceuticals Corporation | $79.69 | 2024-2025 | |
| W. L. Gore & Associates, INC. | $79.08 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $77.13 | 2019 | |
| Glaxosmithkline, LLC. | $54.08 | 2022 | |
| Akebia Therapeutics INC | $49.58 | 2021-2024 | Vafseo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $46.38 | 2022 | |
| Janssen Pharmaceuticals, INC | $39.21 | 2021-2022 | |
| Horizon Therapeutics Plc | $33.26 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.95 | 2023 | Gattex |
| Aurinia Pharma U.S., INC. | $13.88 | 2023 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asad Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.